Securities Class Action Filed Against Hims & Hers Health: Investors Urged to Take Action Before Deadline

Hims & Hers Health Faces Securities Class Action

Hims & Hers Health, Inc. (NYSE: HIMS), along with certain executives, is currently embroiled in a securities class action lawsuit following serious allegations of misconduct from the Federal Trade Commission (FTC). This lawsuit comes in response to the FTC's broad complaint against the company, which accuses it of significant business improprieties regarding the handling of consumer health data.

Hagens Berman, a law firm representing investors, is leading the charge in this case, seeking to hold the company accountable for any losses experienced by investors. They encourage those affected to submit their claims now, particularly with the deadline for lead plaintiffs approaching on November 2, 2026. The class period defined for this lawsuit runs from August 4, 2025, to July 29, 2026.

The core of the lawsuit is tied to Hims' marketing assurances about their commitment to protecting consumer health information. Allegations suggest that, contrary to these assurances, Hims shared sensitive personal health data with third-party advertising networks without proper consent. Specifically, the company is said to have used tracking mechanisms to relay this information to platforms like Meta (formerly Facebook) and Snap, undermining their promises of user privacy.

Furthermore, the complaint outlines issues with Hims' subscription model. It claims that the company enrolled consumers in recurring subscriptions without their clear consent, billed them for prescriptions immediately upon filling out intake forms, and misled them into thinking they could consult with a healthcare provider first. This method of operation has triggered significant regulatory concerns, with the FTC and other state regulators asserting that these practices violate consumer protection laws, specifically the Restore Online Shoppers' Confidence Act (ROSCA).

On July 29, 2026, Hims' stock took a substantial hit, falling by 14.7%, equating to a loss exceeding $970 million in market capitalization in a single trading day. Experts attribute this sharp decline directly to the revelations from the FTC's allegations, revealing how precarious Hims' position is amidst growing scrutiny.

Reed Kathrein, a partner at Hagens Berman, expressed concerns regarding whether Hims intentionally misled investors. As the investigations unfold, there is a growing need for investors to come forward and share any information or losses incurred during this time.

The firm also welcomes whistleblowers who may have non-public information regarding Hims' practices and offers rewards under the SEC Whistleblower program, where those providing original information can receive up to 30% of any successful SEC recovery. Investors and whistleblowers can connect with Hagens Berman at [email protected] or by calling 844-916-0895.

In the realm of corporate accountability, Hagens Berman has established a reputation as a formidable advocate, having secured over $2.9 billion for clients affected by corporate negligence and misconduct. Their commitment to safeguarding investors' rights and pursuing justice is underscored by their proactive handling of this case against Hims & Hers Health.

As this legal battle unfolds, investors are advised to keep a close watch on developments and to take swift action if they have been affected by Hims' practices, ensuring they can present their claims before the upcoming deadline.